Q&A with Hans Engels, Business Unit President and CEO of DSM Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Hans Engels, Business Unit President and CEO of DSM Pharmaceuticals

Pharmaceutical Technology
Volume 33, Issue 11

PharmTech:




What is the biggest industry challenge you're now facing?

Engels:

With the complexity we have in the supply chain for pharmaceutical products, it is absolutely necessary that the different elements of the supply chain interact much closer together than they have done in the past. Previously, a large pharmaceutical company controlled everything from the top down. By having enough excess capacity in all elements of the supply chain, they were able to fulfill the paradigm of always having product available in the marketplace.

Now this is going away. Now you have high-performing elements in your network that might be your own facility or might be somebody else's facility. You need to make sure that the information exchange between these elements in the network is flawless so that if there is any problem in one element of the network, everybody else becomes aware of it and can take appropriate action. The paradigm is still that product has to be available at all times in the marketplace. If you don't have product, that's the most costly failure you can have.

PharmTech:

A lot of people talk about just-in-time manufacturing, but do you think many pharmaceutical companies are actually trying to do it?

Engels:

If you want to apply it in the pharmaceutical industry, a lot of minds have to change. I think the pharmaceutical industry is far away from on-demand manufacturing for multiple reasons. One of the reasons is the culture of the industry, other reasons are compliance constraints. But I think this should not prevent us from getting as close as possible to that paradigm.

PharmTech:

Has DSM tried new ways of exchanging information with its clients?

Engels:

Yes. For instance, the whole supply chain must know about the progress of deviations in the quality system. We created a dashboard that tracks deviation handling throughout manufacturing, quality assurance, and the laboratories. Because we have not found a way to directly and securely tie clients into our systems, we created data rooms that are automatically updated so the customer can see data we have agreed upon up front that they want to see.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here